NEW YORK, July 8 — The idea that your own body could be trained to hunt down and kill cancer has been around longer than most people realize. It dates back to the 1890s, when a surgeon named William Coley started injecting bacteria directly into tumors, hoping to jolt the immune system into action. His approach, known as Coley’s toxins, was a crude but visionary start.
More than a century later, that same basic instinct — get the immune system to recognize cancer as the enemy — has spawned a multi-billion-dollar field that is reshaping how we think about treatment. Think of it like this: your immune system is a highly trained security force, but cancer cells are masters of disguise.
They learn to flash the right ID badges, telling the guards, “I’m one of you, no need to check.” Immunotherapy, in its modern forms, is the technology that strips those fake badges away or, in some cases, retrains the guards to recognize the intruders no matter what they’re wearing. The practical upshot for patients has been dramatic in certain cancers. Before 2011, the five-year survival rate for metastatic melanoma — the deadliest form of skin cancer — hovered between 5 and 10 percent.
That was the grim reality. Then came a new class of drugs called checkpoint inhibitors.
The first of these, ipilimumab, sold as Yervoy, won FDA approval in 2011 for melanoma. It works by blocking a protein called CTLA-4, a kind of brake on the immune system. Three years later, in 2014, pembrolizumab, known as Keytruda, was approved for melanoma as well.
It targets a different brake, PD-1. Since then, the FDA has approved more than ten checkpoint inhibitors for a wide range of cancers. The result?
Five-year survival rates for metastatic melanoma have jumped to over 50 percent. That is not a cure for everyone, but it is a staggering leap in a single decade.
The mechanism is worth explaining in plain terms. T cells are the foot soldiers of the immune system. They patrol the body looking for trouble.
But they have built-in safety switches — proteins like PD-1 and CTLA-4 — that tell them to stand down when they encounter a healthy cell. Cancer cells exploit this.
They display the same signals, tricking the T cells into thinking everything is fine. Checkpoint inhibitors block those signals. They flip the safety switch to “off.” The T cells, now unleashed, can attack the tumor.
That is one approach. Another is far more personalized and, frankly, sounds like science fiction. It is called CAR-T cell therapy.
Here is how it works: doctors take a sample of a patient’s own T cells. In the lab, they engineer those cells to express a special receptor — a chimeric antigen receptor, or CAR — that is designed to lock onto cancer cells.
Then they infuse the modified cells back into the patient. These are now living drugs, programmed to seek and destroy. The first CAR-T therapy, tisagenlecleucel, sold as Kymriah, was approved by the FDA in August 2017 for B-cell acute lymphoblastic leukemia, a cancer of the blood.
As of 2023, six CAR-T therapies have been approved. The practical upshot: for some patients with blood cancers who had run out of options, these engineered cells have produced remissions that were previously unthinkable.
Immunotherapy is not entirely new. Monoclonal antibodies have been around for decades. Rituximab, sold as Rituxan, was approved in 1997 for non-Hodgkin lymphoma.
Trastuzumab, known as Herceptin, followed in 1998 for HER2-positive breast cancer. These are antibodies made in a lab that target specific antigens on cancer cells, flagging them for destruction. They were the first wave of targeted immunotherapy, long before checkpoint inhibitors became household names.
Then there are cancer vaccines. Some are preventive.
The HPV vaccine, Gardasil, was approved in 2006. The hepatitis B vaccine was approved even earlier, in 1986. Both prevent viruses that can cause cancer.
Others are therapeutic — they treat existing cancer. The first of these, sipuleucel-T, sold as Provenge, was approved in 2010 for prostate cancer.
It is a personalized vaccine made from a patient’s own immune cells, trained to attack prostate cancer cells. The global market for all these approaches reflects the scale of the opportunity. In 2022, the cancer immunotherapy market was valued at $126 billion.
Projections put it at $250 billion by 2030. That kind of money fuels research, and research is already producing results that would have been hard to believe twenty years ago. The field is moving fast.
Researchers are working on combining checkpoint inhibitors with other treatments, on making CAR-T therapy work for solid tumors — which has been a tougher nut to crack — and on developing next-generation vaccines. The goal is to make immunotherapy work for more cancers and more patients.
The history here matters. William Coley’s bacterial injections in the 1890s were dismissed by many of his peers. It took more than a hundred years for the science to catch up to his intuition.
Now, the immune system is no longer an afterthought in cancer treatment. It is a central pillar.
{“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “New Cancer Immunotherapy Treatments Boost Immune System to Fight Tumors”, “description”: “NEW YORK, July 8 — The idea that your own body could be trained to hunt down and kill cancer has been around longer than…”, “datePublished”: “2026-07-08T09:30:00+00:00”, “author”: {“@type”: “Person”, “name”: “Erika Johnson”}, “publisher”: {“@type”: “Organization”, “name”: “InfoPulse Today”, “url”: “https://newsfeed.infopulsetoday.com/”}}
